Launched 2021, T21 has been a Milestone in Medical Cannabis Research and Accessibility.
After five transformative years, Drug Science ‘s T21 (Project Twenty21)—the UK’s largest medical cannabis patient registry—has reached the conclusion of its data collection phase. This marks a pivotal moment in the evolution of medical cannabis treatment, policy, and practice. The insights gathered on a wide range of conditions from chronic pain to anxiety, epilepsy and more, will have a lasting impact on future treatments and regulatory frameworks of cannabis-based therapies.
About T21: What Was It All About?
T21 was launched with the mission of bridging the gap between the medical use of cannabis and evidence-based healthcare policy. It offered patients access to qualifying Cannabis-Based Medicinal Products (CBMPs) at a discounted price while collecting real-world data to support their safety, effectiveness, and accessibility. By making treatment more affordable, T21 not only supported thousands of patients with chronic conditions, but also built one of the most comprehensive datasets on medical cannabis in the UK to date.
The project wasn’t just about patient care—it was about shaping the future. The data collected will play a critical role in building the case for NHS funding of medical cannabis treatments. With this wealth of real-world evidence, Drug Science will continue advocating for cannabis-based treatments to become a mainstream option in the UK’s healthcare system.
What the Data Means for Patients and Policy
The insights gained through T21 represent a significant step forward in understanding how CBMPs can treat a variety of health conditions. These findings have contributed to the growing accumulation of evidence that will inform future healthcare guidelines, influence regulatory frameworks, and guide both public and clinical attitudes toward medical cannabis.
While T21’s data collection phase has ended, the research does continues. Its legacy will shape future studies, providing a foundation for greater scientific inquiry and practical applications. The thousands of patient experiences documented through T21 will continue to drive innovation in treatment and inform crucial policy decisions.
What’s Next for Patients at Lyphe Clinic?
As T21 concludes, Lyphe Clinic has already started the transition to a more inclusive model for affordable medical cannabis treatments. Previously, T21 patients benefited from reduced pricing under the project’s access scheme. Moving forward, Lyphe Clinic is committed to bringing prices down across the board for all patients—without requiring participation in a specific program.
This shift ensures sustainable, consistent, and affordable access for everyone in need. Additionally, Lyphe is working to improve stock levels with our partnership with Gro-Vida, so patients can rely on consistent, high-quality products for their care.
A New Chapter for Medical Cannabis in the UK
Although the T21 project is finishing, its influence will resonate for years to come. By building one of the largest datasets on medical cannabis, T21 has helped to bridge the gap between anecdotal evidence and scientific rigor.
To read more about Lyphe’s approach to affordable medical cannabis care, click here.
Related Insights
Whilst you’re here you might also like to read…
